Thomas Lindenstrøm

Research

My research is centered on the interactions between host and pathogen. As part of Tuberculosis (TB) Vaccine Research, the main goal of my research is to develop a new and improved vaccine against infection with Mycobacterium tuberculosis (Mtb). My focus is within basic and preclinical research in order to understand the mechanisms that lead to protective immunity to Mtb. This includes both natural immunity to infection with Mtb as well as prophylactic and therapeutic vaccination strategies that aim to mediate local protection within the lung.

Research areas:

• T cell immunity and T cell memory
• T cell migration during Mtb infection
• Immune mediated protection vs. pathology of the lung
• Animal models for evaluation of pre vs. post exposure vaccines

Responsibilities

• Internal and external research projects, including scientific project leader of NIH project: “Eliciting lung-localized CD4 T cell responses against Mycobacterium tuberculosis in preventive and post-exposure settings”
• Biosafety and Biosecurity of BSL-3 laboratories

Publications

• Darrah, P. A., DiFazio, R. M., Maiello, P., Gideon, H. P., Myers, A. J., Rodgers, M. A., Hackney, J. A., Lindenstrøm, T., Evans, T., Scanga, C. A., Prikhodko, V., Andersen, P., Lin, L. L., Laddy, D., Roederer, M., Seder, R. A., Flynn, J. L. (2019). Boosting BCG with proteins or rAd5 does not enhance protection against tuberculosis in rhesus macaques. npg Vaccine, 4:21.
• Billeskov, R., Lindenstrøm, T., Woodworth, J., Vilaplana, C., Cardona, P. J., Cassidy, J., Mortensen, R., Agger, E. M.; Andersen, P. (2018). High antigen dose is detrimental to post exposure vaccine protection against tuberculosis. Frontier in Immunology, 8: 1978.
• Lindenstrøm, T., Moguche, A., Damborg, M., Agger, E. M.; Urdahl, K., Andersen, P. (2018). T cells primed by live mycobacteria versus a tuberculosis subunit vaccine exhibit distinct functional properties. EbioMedicine, 27, 27-39.
• Lindenstrøm, T., Aagaard, C., Christensen, D., Agger, E. M.; Andersen, P. (2014). High-frequency vaccine-promoted CD8 T cells specific for an epitope naturally processed during infection with M. tuberculosis do not confer protection. European Journal of Immunology, 44, 1699-1709.
• Knudsen, N. P. H., Nørskov-Lauritsen, S., Dolganov, G., Schoolnik, G. K., Lindenstrøm, T.; Andersen, P., Agger, E. M.; Aagaard, C. (2014). New protective TB vaccine with high predicted population coverage and compatibility with modern diagnostics. Proc. Natl. Acad. Sci. U. S. A., 111, 1096-1101.